Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
4.000
-0.510 (-11.31%)
At close: Apr 1, 2025, 4:00 PM
4.162
+0.162 (4.06%)
After-hours: Apr 1, 2025, 4:39 PM EDT
Immatics Revenue
In the year 2024, Immatics had annual revenue of 155.84M EUR with 188.60% growth. Immatics had revenue of 56.25M in the quarter ending December 31, 2024, with 253.32% growth.
Revenue (ttm)
155.84M EUR
Revenue Growth
+188.60%
P/S Ratio
3.04
Revenue / Employee
291,280 EUR
Employees
535
Market Cap
486.20M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IMTX News
- 4 days ago - Immatics N.V.: Trading Below Cash, But Not Without Reason - Seeking Alpha
- 5 days ago - Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 4 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 5 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire
- 6 months ago - Immatics: A Promising TCR Pipeline - Seeking Alpha
- 6 months ago - Immatics Announces Pricing of $150 Million Public Offering - GlobeNewsWire
- 6 months ago - Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? - Benzinga
- 6 months ago - Immatics Announces Proposed $150 Million Public Offering - GlobeNewsWire